---
document_datetime: 2023-09-21 21:01:45
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/breyanzi-epar-all-authorised-presentations_en.pdf
document_name: breyanzi-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.6471537
conversion_datetime: 2025-12-21 18:25:18.970825
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength                                      | Pharmaceutical Form     | Route of Administration   | Immediate Packaging   | Content (concentration)   | Pack size                           |
|------------------|-------------------|-----------------------------------------------|-------------------------|---------------------------|-----------------------|---------------------------|-------------------------------------|
| EU/1/22/1631/001 | Breyanzi          | 1.1-70 × 10 6 cells/mL / 1.1-70 × 10 cells/mL | Dispersion for infusion | Intravenous use           | vial (COC)            | 4.6 ml per vial           | 1 to 4 vials of each cell component |